---
title: Cardiovascular Drugs
type: overview
phase: 1
status: complete
priority: high
tags: [cardiovascular, antihypertensives, antiarrhythmics, anticoagulants, lipid-lowering, heart-failure]
created: 2025-11-08
last_modified: 2025-11-08
---

# Cardiovascular Drugs

## Overview

Cardiovascular drugs are among the most commonly prescribed medications worldwide. They treat hypertension, heart failure, arrhythmias, coronary artery disease, and thromboembolic disorders. Understanding these drugs is essential for internal medicine, cardiology, emergency medicine, and primary care.

## Subdirectory Contents

### 1. Antihypertensives
Comprehensive coverage of drugs used to treat hypertension, including:
- ACE inhibitors (enalapril, lisinopril, ramipril)
- Angiotensin II receptor blockers/ARBs (losartan, valsartan)
- Beta-blockers (metoprolol, atenolol, carvedilol)
- Calcium channel blockers (amlodipine, diltiazem, verapamil)
- Diuretics (thiazides, loops, K+-sparing)
- Direct vasodilators (hydralazine, minoxidil)
- Central agents (clonidine, methyldopa)
- Alpha-blockers (doxazosin, prazosin)

### 2. Antiarrhythmics
Drugs for managing cardiac arrhythmias:
- **Class I** (Sodium channel blockers): Ia, Ib, Ic
- **Class II** (Beta-blockers): Propranolol, metoprolol, esmolol
- **Class III** (Potassium channel blockers): Amiodarone, sotalol, dofetilide
- **Class IV** (Calcium channel blockers): Verapamil, diltiazem
- **Other**: Adenosine, digoxin, magnesium

### 3. Anticoagulants
Drugs preventing thrombosis:
- Warfarin (vitamin K antagonist)
- Heparins (unfractionated, LMWH, fondaparinux)
- Direct oral anticoagulants (DOACs): Dabigatran, rivaroxaban, apixaban, edoxaban
- Antiplatelet agents: Aspirin, clopidogrel, ticagrelor, prasugrel
- Thrombolytics: Alteplase, tenecteplase, streptokinase

### 4. Lipid-Lowering Drugs
Drugs for dyslipidemia management:
- Statins (atorvastatin, simvastatin, rosuvastatin)
- Fibrates (fenofibrate, gemfibrozil)
- PCSK9 inhibitors (evolocumab, alirocumab)
- Ezetimibe (cholesterol absorption inhibitor)
- Bile acid sequestrants (cholestyramine, colesevelam)
- Niacin (nicotinic acid)
- Omega-3 fatty acids (icosapent ethyl)

## Clinical Importance

### Cardiovascular Disease Burden
- #1 cause of death worldwide
- Hypertension affects 1 in 3 adults
- Heart failure: 6 million Americans
- Atrial fibrillation: Most common arrhythmia
- Stroke: 5th leading cause of death

### Treatment Goals
1. **Hypertension**: BP <130/80 mmHg (ACC/AHA 2017)
2. **Dyslipidemia**: LDL <70 mg/dL (high-risk patients)
3. **Heart failure**: Reduce mortality, improve symptoms
4. **Arrhythmias**: Rate/rhythm control, prevent stroke
5. **Anticoagulation**: Prevent thromboembolism while minimizing bleeding

## Key Drug Classes

### Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

**ACE Inhibitors (ACE-I)**:
- Mechanism: Block ACE → ↓Angiotensin II, ↓aldosterone
- Benefits: ↓Mortality in HF, post-MI; renoprotection
- Side effects: Cough (10-20%), hyperkalemia, angioedema
- Contraindications: Pregnancy, bilateral renal artery stenosis

**ARBs**:
- Mechanism: Block AT1 receptors
- Similar benefits to ACE-I
- Less cough (no bradykinin accumulation)
- Alternative when ACE-I not tolerated

**Aldosterone Antagonists**:
- Spironolactone, eplerenone
- ↓Mortality in HF
- Risk: Hyperkalemia, gynecomastia (spironolactone)

### Diuretics

**Thiazides** (HCTZ, chlorthalidone):
- First-line for hypertension
- Mechanism: Block Na/Cl cotransporter (DCT)
- Side effects: Hypokalemia, hyponatremia, hyperuricemia, hyperglycemia

**Loop Diuretics** (furosemide, bumetanide, torsemide):
- Most potent diuretics
- Mechanism: Block Na/K/2Cl cotransporter (loop of Henle)
- Uses: Heart failure, edema, hypercalcemia
- Side effects: Hypokalemia, ototoxicity, hypovolemia

**K+-Sparing** (spironolactone, amiloride, triamterene):
- Prevent hypokalemia
- Risk: Hyperkalemia (esp. with ACE-I/ARBs)

### Beta-Blockers

**Cardioselective** (β1): Metoprolol, atenolol, bisoprolol
**Non-selective** (β1/β2): Propranolol, nadolol, timolol
**Mixed α/β**: Labetalol, carvedilol

**Uses**: Hypertension, heart failure, post-MI, arrhythmias, angina

**Contraindications**: Asthma (non-selective), decompensated HF, bradycardia, heart block

### Calcium Channel Blockers

**Dihydropyridines** (amlodipine, nifedipine):
- Peripheral vasodilation
- Minimal cardiac effects
- Side effects: Peripheral edema, flushing

**Non-dihydropyridines** (verapamil, diltiazem):
- ↓HR, ↓AV conduction
- Uses: Rate control (AFib), hypertension, angina
- Avoid with β-blockers (additive AV block)

### Statins

**Mechanism**: HMG-CoA reductase inhibition → ↓cholesterol synthesis

**High-intensity**: Atorvastatin 40-80 mg, rosuvastatin 20-40 mg
**Moderate-intensity**: Atorvastatin 10-20 mg, simvastatin 20-40 mg

**Benefits**: ↓LDL, ↓cardiovascular events, ↓mortality (proven benefit)

**Side effects**: Myalgia, rhabdomyolysis (rare), ↑liver enzymes, diabetes

### Anticoagulants

**Warfarin**:
- Vitamin K antagonist
- INR monitoring required (target 2-3 usually)
- Drug/food interactions
- Reversal: Vitamin K, PCC, FFP

**DOACs** (dabigatran, rivaroxaban, apixaban, edoxaban):
- Predictable pharmacokinetics
- No routine monitoring
- Fewer drug/food interactions
- Specific reversals available (idarucizumab, andexanet alfa)

**Heparins**:
- Unfractionated (IV/SC): Monitor aPTT
- LMWH (enoxaparin): Weight-based dosing, no monitoring (usually)

## Clinical Pearls

1. **ACE-I cause cough**: Due to bradykinin accumulation (10-20%)
2. **ARBs don't cause cough**: Alternative for ACE-I intolerance
3. **Spironolactone in HF**: ↓Mortality (RALES trial)
4. **Beta-blockers in HF**: Start low, go slow; carvedilol, bisoprolol, metoprolol succinate
5. **Statins first-line for dyslipidemia**: Proven mortality benefit
6. **DOACs preferred over warfarin**: Easier management, less monitoring
7. **Amiodarone most effective antiarrhythmic**: But significant toxicity
8. **Verapamil/diltiazem + beta-blockers**: Avoid (AV block risk)
9. **Thiazides first-line for HTN**: Per JNC 8, ACC/AHA
10. **Loop diuretics for fluid overload**: Heart failure, edema

## Exam Focus

### High-Yield Topics
1. Mechanism of action for each drug class
2. Side effects and contraindications
3. Drug interactions (warfarin, statins + azoles)
4. Indications: When to use which drug
5. Vaughan Williams classification (antiarrhythmics)
6. RAAS pharmacology
7. Anticoagulation reversal agents
8. Heart failure guideline-directed medical therapy
9. Hypertension treatment algorithms
10. Statin intensity and indications

### Common Question Types
- Match drug to mechanism/class
- Identify contraindications
- Manage drug toxicity/overdose
- Select appropriate therapy for clinical scenario
- Predict side effects from mechanism
- Drug-drug interactions

## Guidelines and Evidence

### Major Trials
- **RALES**: Spironolactone in HF
- **SOLVD**: Enalapril in HF
- **JUPITER**: Rosuvastatin for primary prevention
- **4S, HPS, PROVE-IT**: Statin trials
- **ARISTOTLE, RE-LY, ROCKET-AF**: DOACs vs warfarin
- **AFFIRM**: Rate vs. rhythm control in AFib

### Current Guidelines
- ACC/AHA Hypertension Guideline (2017)
- ACC/AHA Heart Failure Guideline (2022)
- ACC/AHA Cholesterol Guideline (2018)
- AHA/ACC/HRS Atrial Fibrillation Guideline (2023)
- ESC Cardiovascular Guidelines

## Key Takeaways

1. **RAAS inhibitors**: ACE-I or ARBs first-line for HF, post-MI, diabetic nephropathy
2. **Diuretics**: Thiazides for HTN, loops for volume overload
3. **Beta-blockers**: Essential in HF (mortality benefit), post-MI, arrhythmias
4. **CCBs**: Vasodilation (dihydropyridines) vs. rate control (non-dihydropyridines)
5. **Statins**: Primary and secondary prevention of ASCVD
6. **Antiarrhythmics**: Class I-IV; amiodarone most effective but toxic
7. **Warfarin**: Requires INR monitoring; many interactions
8. **DOACs**: Preferred for AFib anticoagulation (vs warfarin)
9. **Aspirin + P2Y12 inhibitor**: Dual antiplatelet therapy post-ACS/PCI
10. **Guideline-directed medical therapy**: Key to improving outcomes

---

Study each drug class in detail, focusing on mechanisms, clinical uses, and side effects. Understanding cardiovascular pharmacology is essential for board exams and clinical practice.
